Head of Investor Relations
Alaunos Therapeutics, Inc. (TCRT)Equibles does not estimate personal net worth.
Get an email with a short summary when Alaunos Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get TCRT alertsAdam Levy is recorded as Head of Investor Relations at Alaunos Therapeutics, Inc. (TCRT). Earlier roles on record: CEO and Board Member at Nexgel, Inc. (NXGL) until August 21, 2026. Nexgel, Inc. reported in an 8-K filed August 21, 2026 that Adam Levy resigned as Board of Directors, effective August 21, 2026. Nexgel, Inc. reported in an 8-K filed August 21, 2026 that Adam Levy was terminated as Chief Executive Officer, effective August 21, 2026. The proxy statement of Nexgel, Inc. reports total compensation of $877,177 for Adam Levy in fiscal 2025, including a base salary of $373,077. Disclosed compensation is on record for 6 fiscal years. Adam Levy has spoken on 13 earnings calls across 2 companies, most recently for Nexgel, Inc. on November 12, 2025. Those appearances were for Nexgel, Inc. (NXGL) and Alaunos Therapeutics, Inc. (TCRT). Alaunos Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls Adam Levy spoke on are classified in the Healthcare sector. Other leadership on record at Alaunos Therapeutics, Inc. includes Dale Curtis Hogue, Jr. (CEO and Board Member), Heidi Hagen (CEO and Board Member), Holger Weis (CEO, Chairman and Board Member) and 7 others.
“Effective August 21, 2026 (the "Separation Date"), NexGel, Inc. (the "Company") terminated Adam R. Levy's employment as Chief Executive Officer without Cause (as defined in Mr. Levy's Executive Employment Agreement, dated July 23, 2026), and Mr. Levy resigned from the Company's Board of Directors (the "Board") and from all other officer, director, committee and fiduciary positions held by him with the Company and its subsidiaries.”
“Effective August 21, 2026 (the "Separation Date"), NexGel, Inc. (the "Company") terminated Adam R. Levy's employment as Chief Executive Officer without Cause (as defined in Mr. Levy's Executive Employment Agreement, dated July 23, 2026), and Mr. Levy resigned from the Company's Board of Directors (the "Board") and from all other officer, director, committee and fiduciary positions held by him with the Company and its subsidiaries.”
“And thank you everyone for joining us today to discuss our third quarter 2025 financial and operating results. For 2025, we reported revenue of $2.9 million, flat year over year and slightly higher sequentially.”
“Thank you, Valter, and thank you, everyone, for joining us today to discuss our second quarter of 2025 financial and operating results.”
“Thank you, Valter, and thank you, everyone, for joining us today to discuss our first quarter of 2025 financial and operating results.”
“Thank you, Maria, and thank you, everyone, for joining us today to discuss our third quarter 2024 financial and operating results. The third quarter of 2024 was yet another record quarter for the company across all of our key financial metrics.”
“Thank you, Valter, and thank you, everyone, for joining us today to discuss our second quarter 2024 financial and operating results. The second quarter of 2024 was a record revenue quarter for the company, totaling $1.44 million, an increase of 23.4% year-over-year and 13.8% sequentially.”
2021-08-30–present
Start not stated–2026-08-21
Start not stated–2026-08-21
Biotechnology · Healthcare
Head of Investor Relations
2021-08-30–present
NXGL
Medical Instruments & Supplies · Healthcare
CEO, Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Nexgel, Inc. (NXGL) | Chief Executive Officer and President | $373,077 | $877,177 |
| 2024 | Nexgel, Inc. (NXGL) | Chief Executive Officer and President | $325,000 | $437,550 |
| 2023 | Nexgel, Inc. (NXGL) | Chief Executive Officer | $325,000 | $442,100 |
| 2022 | Nexgel, Inc. (NXGL) | Chief Executive Officer | $300,000 | $450,104 |
| 2021 | Nexgel, Inc. (NXGL) | Chief Executive Officer | $180,000 | $306,482 |
| 2020 | Nexgel, Inc. (NXGL) | Chief Executive Officer | $143,077 | $226,077 |
